Evidence map›Paper›PMID 39133438›Full record

Trial reportJournal of patient-reported outcomes2024

The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation.

David Cella, Christine de la Loge, Fatoumata Fofana, Shien Guo, Alicia Ellis, Carmen Fleurinck, Ute Massow, Maxime Dougados, Victoria Navarro-Compán, Jessica A Walsh

2 registry-linked trialsAbstract readClinical Trial, Phase III
In one paragraph

Trial report in Journal of patient-reported outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03928704 phase3completednot on this map

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

TypeinterventionalSponsorUCB Biopharma SRLRan2019 to 2023Enrolled274ConditionsNonradiographic Axial SpondyloarthritisArmsBimekizumab, Placebo
NCT03928743 phase3completednot on this map

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

TypeinterventionalSponsorUCB Biopharma SRLRan2019 to 2022Enrolled332ConditionsAnkylosing SpondylitisArmsBimekizumab, Placebo
3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David Cella *Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA. axSpAFacit-Fatigue@costellomedical.com.
Christine de la Loge *PCOM Analytics, Avallon, France.
Fatoumata FofanaEvidera, Zonneoordlaan, Netherlands.
Shien GuoEvidera, Waltham, MA, USA.
Alicia EllisUCB Pharma, Raleigh, NC, USA.
Carmen FleurinckUCB Pharma, Brussels, Belgium.
Ute MassowUCB Pharma, Monheim, Germany.
Maxime DougadosDepartment of Rheumatology, Hôpital Cochin, University Paris Cité, Paris, France.
Victoria Navarro-CompánDepartment of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain.
Jessica A WalshSalt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFatigue is an important symptom for most patients with axial spondyloarthritis (axSpA). The FACIT-Fatigue is a 13-item patient-reported outcome (PRO) instrument that has been used in axSpA clinical trials to measure fatigue severity and impact on daily activities. However, the psychometric properties of the FACIT-Fatigue are not fully evaluated across the entire spectrum of axSpA including non-radiographic axSpA (nr-axSpA) and radiographic axSpA (r-axSpA). This study determined: (1) the psychometric properties of the FACIT-Fatigue in nr-axSpA, r-axSpA, and the broad axSpA population and (2) FACIT-Fatigue scores representing meaningful within-patient change (MWPC), meaningful between-group differences, and cross-sectional severity bands.

methodsData from two Phase 3 trials in adults with nr-axSpA (BE MOBILE 1; N = 254) and r-axSpA (BE MOBILE 2; N = 332) were analyzed pooled and separately to assess the psychometric properties of the FACIT-Fatigue. MWPC and meaningful between-group difference estimates were derived using anchor-based and distribution-based methods. Cross-sectional fatigue severity bands were estimated using logistic regression analysis.

resultsThe FACIT-Fatigue presented good internal consistency, adequate convergent and known-groups validity, and was sensitive to change over time across the full axSpA spectrum. A 5-11-point increase in FACIT-Fatigue score was estimated to represent a MWPC, with an 8-point increase selected as the responder definition. A 2.14-5.34-point difference in FACIT-Fatigue score change over a 16-week period was estimated to represent a small-to-medium meaningful between-group difference. FACIT-Fatigue score severity bands were defined as: none or minimal (>40), mild (>30 to ≤40), moderate (>21 to ≤30), and severe (≤21).

conclusionsThese findings support the use of the FACIT-Fatigue as a fit-for-purpose measure to assess fatigue-related treatment benefit in axSpA clinical trials. The proposed score estimates and thresholds can guide FACIT-Fatigue score interpretation across the full axSpA spectrum.

trial registrationClinicalTrials.Gov, NCT03928704. Registered 26 April 2019-Retrospectively registered, https://classic. CLINICALTRIALS: gov/ct2/show/NCT03928704 . CLINICALTRIALS: Gov, NCT03928743. Registered 26 April 2019-Retrospectively registered, https://classic. CLINICALTRIALS: gov/ct2/show/NCT03928743 .

Indexed as

Axial SpondyloarthritisFatiguePatient Reported Outcome MeasuresPsychometricsSeverity of Illness IndexAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedReproducibility of ResultsAnkylosing spondylitisAxial spondyloarthritisFACIT-FatigueFatigueMeaningful between-group differenceMeaningful within-patient changeNon-radiographic axial spondyloarthritisPsychometric propertiesSeverity bands

Identifiers

PMID39133438
PMCPMC11319684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.